5 patents currently held
31 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2038. from the record
Of the 31 now held by other companies, 20 name Open Text Inc. as their current owner, and 11 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2038
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Aug 2038 · High confidence
Also notable
Ends Jan 2039 · Medium confidence
Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
US 11,136,334
Granted 2021. Computed term ends 2038.
Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
US 11,407,759
Granted 2022. Computed term ends 2039. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Mar 2035 · High confidence
The most cited patent in this portfolio, cited by 85 later US patents, top 5% of utility patents granted in 2017 in our data. Protection runs to 2035.
now held by Open Text Inc.
Also notable
Ends Dec 2034 · High confidence
Cited by 8 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2034.
merged into Open Text Holdings Inc. - now held by Open Text Inc.
Also notable
Ends Aug 2034 · High confidence
Cited by 10 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2034.
now held by Open Text Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,136,334 | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione held by Actuate Therapeutics Inc. In force · High confidence | In force | High confidence | |
| US 12,116,374 | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione held by Actuate Therapeutics Inc. In force · High confidence | In force | High confidence | |
| US 11,407,759 | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione held by Actuate Therapeutics Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,741,973 | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione held by Actuate Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 12,145,943 | Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione held by Actuate Therapeutics Inc. In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 5: 31 patents in force now held by others · 7 patents ended · 4 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
6 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed